You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Effect of CPAP on the metabolic syndrome: a randomised sham-controlled study
  1. CM Hoyos1,
  2. DR Sullivan2,
  3. PY Liu1,3
  1. 1 Endocrine and Cardiometabolic Research Group, NHMRC Centre for Integrated Research and Understanding of Sleep (CIRUS), Woolcock Institute of Medical Research , University of Sydney, Sydney, New South Wales, Australia
  2. 2 Biochemistry Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
  3. 3 Division of Endocrinology, Department of Medicine, David Geffen School of Medicine at UCLA, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California, USA
  1. Correspondence to Dr Peter Y Liu, Division of Endocrinology, Department of Medicine, David Geffen School of Medicine at UCLA, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, 1124 W. Carson Street, Torrance, CA 90502, USA; pliu{at}labiomed.org

https://doi.org/10.1136/thoraxjnl-2012-203074

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A recently published editorial1 concluded that severity of disease, Continuous Positive Airway Pressure (CPAP) compliance and comorbidities might explain discrepancies between a randomised sham-controlled crossover study2 which showed that CPAP reversed metabolic syndrome (metS) and reduced weight, body mass index (BMI) and visceral abdominal fat and our findings from a randomised sham-controlled parallel-group study.3 Whether CPAP might be a novel method to reverse metS in those with Obstructive Sleep Apnea (OSA) is an intriguing possibility, since diagnosing and treating metS is important.1 We omitted to examine the effect of CPAP on metS in our population, a typical OSA cohort with treated long-standing metabolic comorbidites and less than ideal CPAP usage.1 To rectify this, we retrospectively assayed stored blood …

    View Full Text

    Footnotes

    • Contributors Study concept and design: PYL; Acquisition of data: CMH, DRS; Analysis and interpretation of data: CMH, PYL; Drafting of the manuscript: CMH, PYL; Critical revision of the manuscript: CMH, DRS, PYL; Statistical analysis: CMH PYL; Obtained funding: PYL.

    • Funding The study was supported by the National Health and Medical Research Council of Australia (NHMRC) through a project grant (512498), a Centre for Clinical Research Excellence in Interdisciplinary Sleep Health (571421) and fellowships to CMH and PYL (512057 and 1025248, respectively). Sham machines were provided by Phillips Respironics.

    • Competing interests None.

    • Ethics approval The study was approved by the Sydney South West Area Health Service Human Research and Ethics Committee (RPAH Zone).

    • Provenance and review Not commissioned; internally peer reviewed.

    • Clinical trials registry Australian New Zealand Clinical Trials Network, http://www.anzctr.org.au, number ACTRN12608000301369.